Polymorphisms in the genes that code for drug-metabolising enzymes, drug transporters,
drug receptors, and ion channels can affect an individual's risk of having an adverse drug …

… also suggest that the metabolism of the antidepressant citalopram, the proton-pump inhibitor
omeprazol (117), and probably the related drugs pantoprazole and lansoprazole (UA Meyer…

Induction of drug metabolism was described more than 40 years ago. Progress in
understanding the molecular mechanism of induction of drug-metabolizing enzymes was made …

The metabolism of the anticonvulsant drug mephenytoin exhibits a genetic polymorphism in
humans, with the poor metabolizer trait being inherited in an autosomal recessive fashion. …

A genetic polymorphism in the metabolism of the anticonvulsant drug (S)-mephenytoin has
been well documented in humans. There are marked interracial differences in the frequency …

In population studies of individuals given the antihypertensive drug debrisoquine 1,3 , two
distinct phenotypes have been described: extensive metabolizers excrete 10–200 times more …

The metabolism of midazolam and tnazolam to their 1 ‘-hydroxy and 4-hydroxy metabolites
was studied in microsomes of 15 human livers. The formation of both metabolites was …

The debrisoquine-4-hydroxylase polymorphism is a genetic variation in oxidative drug
metabolism characterized by two phenotypes, the extensive metabolizer (EM) and poor …

To standardize CYP2D6 allele nomenclature, and to conform with international human gene
nomenclature guidelines, an alternative to the current arbitrary system is described. Based …

… Meyer UA. Debrisoquine oxidation polymorphism: pheno… Legrand M., Lo-Guidice JM,
Boone P Meyer UA. An efficient … Boone P Meyer UA, A nonsense mutation in the cytochrome …